Literature DB >> 12712786

Use of oral and implantable naltrexone in the management of the opioid impaired physician.

G K Hulse1, G O'Neil, M Hatton, M J Paech.   

Abstract

Doctors are at an increased risk for prescription drug use, particularly opioids and benzodiazpines. This use can interfere with work function and has major potential negative implications for patient safety. Oral naltrexone, an opioid antagonist, has been used as part of a management strategy for opioid dependent physicians. While some patients stabilize on oral naltrexone, others relapse to opioid use. An alternative method of naltrexone maintenance involves the injection or surgical insertion of a sustained release preparation of naltrexone. This approach dramatically improves compliance, removing the onus from the previously opioid impaired physician to use daily oral naltrexone. This article describes the cases of four opioid-impaired doctors who received naltrexone (either oral or implant) as part of their management. The authors conclude that monitoring daily oral naltrexone use and detecting early opioid relapse is difficult, placing both the opioid impaired physician and their patients at risk. In contrast, by using implantable naltrexone, compliance is assured and opioid abstinence can virtually be guaranteed for five months. It is argued that naltrexone implants offer a level of protection not achieved with any previous treatment. It is recommended that management should involve early and close collaboration between the treating doctor and the Medical Board, with initial treatment, ongoing monitoring and follow-up being a Medical Board requirement for registration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12712786     DOI: 10.1177/0310057X0303100211

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  2 in total

1.  Mandatory naltrexone treatment prevents relapse among opiate-dependent anesthesiologists returning to practice.

Authors:  Lisa J Merlo; William M Greene; Raymond Pomm
Journal:  J Addict Med       Date:  2011-12       Impact factor: 3.702

2.  Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program.

Authors:  A S Reece
Journal:  Subst Abuse Treat Prev Policy       Date:  2007-11-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.